Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 20:48:35·⟳ 抓取 20:49:31 +56s·⚡ 决策 10-21 20:51:20 +1m49s·5.8 天前
Summit Therapeutics 与 ECOG-ACRIN 合作启动 ivonescimab 一线胆道癌 II/III 期试验（旧闻转载，无新增事实）
本篇是 Investing.com 对 Summit 官方新闻稿的 AI 改写转载；同一具体催化（EA2251 胆道癌 II/III 期合作）已于今日 10:17 UTC 由本臂处理并判不做，本条无任何新增金额、规模、读出或官方进展，且事件本身为低 materiality 的学术协作组试验启动软催化。
📄 原文Investing.com↗ 原文
Summit Therapeutics begins biliary tract cancer trial for ivonescimab
SpaceX, Tesla shares rise after Musk says committees exploring possible merger HONG KONG - Summit Therapeutics Inc. (NA…
不做 Summit Therapeutics（SMMT.US）
同一 EA2251 胆道癌 II/III 期合作公告今日 10:17 UTC 已研判判不做，本条为 Investing.com AI 改写转载、无新增事实；学术协作组供药型试验无金额/规模/读出，盘前仅微涨且量极薄，无正期望 edge
不做 康方生物（09926.HK）
EA2251 在 Summit 授权区域由 ECOG-ACRIN 主导，对康方无新增付款或权益触发；同一消息已在今日港股盘中消化（+1.53%），无增量可交易
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Investing.com 稿复述的 EA2251 胆道癌 II/III 期合作与 2.5 小时前已研判的 Summit 官方公告完全同一事件、无新增事实；该试验无金额/入组规模/读出时点，BTC 瘤种小且公司已有同适应症 HARMONi-GI1 III 期，缺乏正期望 edge，不做。
消息传播链
- 官方首发 EA2251 胆道癌一线 II/III 期合作，本臂同日 10:17 UTC 已据此判不做
- 对官方新闻稿的滞后改写转载，无新增事实；正文开头误植 SpaceX/Tesla 标题，进一步印证为自动生成稿
关键理由
- 事件方向虽偏正面（第七项国际注册性 II/III 期、叠加中国 HARMONi-GI1 阳性 OS），但属 ECOG-ACRIN 主导的学术协作组供药研究，Summit 无新增自有注册数据或商业里程碑
- 同一 IR 公告今日 10:17 UTC 已判不做，本条为 AI 聚合站改写转载，无信息增量
主要风险
- 10 月 25 日 ESMO 主席研讨会 HARMONi-GI1 详细数据若超预期可能驱动股价，但那是独立的下一个催化，不应以本条试验启动消息提前博
- 若后续披露 EA2251 入组规模、NCI 资助额度或 Summit 主导地位变化，可改变 materiality 判断
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-21 · 影响 supports
官方新闻稿仅含设计描述和 Q4 2026 中心激活，无入组人数、资助金额或数据读出时点；同适应症 HARMONi-GI1 III 期已存在，增量期权有限
检索:ivonescimab biliary tract cancer EA2251 ECOG-ACRIN trial size funding readout 原文 ↗
先例如何影响了这次决策
对本次决策的影响:维持前次不做结论，未产生任何交易腿
方向:重复消息早停，未再做先例统计；前次研判已认定学术协作组试验启动属低弹性软催化
涨幅量级:无可用于校准的新增高相似对齐先例，且本条无新增事实，无需据此定 tp/sl
形态:盘面仅小幅正反应（SMMT 盘前 +1.3%、康方 +1.53%），不支持重大重定价
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,456 ms
{"result": "search_processed_events:agent query=`akeso 9926 ivonescimab 胆道癌 临床试验 | ivonescimab biliary tract cancer nct07765433 harmoni-gi1 esmo 2026 | summit therapeutics ivonescimab biliary tract cancer phase ii/iii ecog-acrin `；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、22847 条本臂决策(完整)，返回 1 条候选。\n• 10-2 - stock_quote 成功 stock_tools HTTP · 343 ms
{ - stock_quote 成功 stock_tools HTTP · 1,123 ms
{ - web_search 成功 doubao_search · 1,675 ms
豆包搜索结果（原始查询:Summit Therapeutics Akeso ivonescimab biliary tract cancer ECOG-ACRIN EA2251 Phase 2/3；API SearchType:web）
原文全文
展开原文 · 2,110 字
SpaceX, Tesla shares rise after Musk says committees exploring possible merger
HONG KONG - Summit Therapeutics Inc. (NASDAQ:SMMT) has entered into a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab in a Phase II/III study for biliary tract cancer, according to a press release statement from its partner Akeso, Inc. (HKEX:9926.HK) issued today.
The study, designated EA2251 (NCT07765433), will assess the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in first-line treatment of patients with advanced biliary tract cancer. Clinical trial site activations in the United States are expected to begin in the fourth quarter of 2026.
This marks the seventh international registrational Phase II/III clinical trial for ivonescimab. The drug is a PD-1/VEGF bispecific antibody developed by Akeso.
A previous Phase III study conducted by Akeso in China, called HARMONi-GI1, evaluated ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for patients with biliary tract cancer and achieved a positive overall survival result.
"EA2251 will explore a novel therapeutic approach in the front-line setting by evaluating ivonescimab with chemotherapy against current immunotherapy-based standards of care," said Deirdre J. Cohen, MD, MS, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai and lead investigator for the study.
Detailed results from the HARMONi-GI1 study will be presented at the European Society for Medical Oncology 2026 Congress on Sunday, October 25.
Akeso has licensed the exclusive rights to develop and commercialize ivonescimab in the United States, Canada, South America, Europe, the Middle East, Africa, and Japan to Summit Therapeutics under an agreement with a total potential value of up to $5 billion.
More than 18 Phase III studies of ivonescimab are currently underway globally across multiple tumor types.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
HONG KONG - Summit Therapeutics Inc. (NASDAQ:SMMT) has entered into a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab in a Phase II/III study for biliary tract cancer, according to a press release statement from its partner Akeso, Inc. (HKEX:9926.HK) issued today.
The study, designated EA2251 (NCT07765433), will assess the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in first-line treatment of patients with advanced biliary tract cancer. Clinical trial site activations in the United States are expected to begin in the fourth quarter of 2026.
This marks the seventh international registrational Phase II/III clinical trial for ivonescimab. The drug is a PD-1/VEGF bispecific antibody developed by Akeso.
A previous Phase III study conducted by Akeso in China, called HARMONi-GI1, evaluated ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for patients with biliary tract cancer and achieved a positive overall survival result.
"EA2251 will explore a novel therapeutic approach in the front-line setting by evaluating ivonescimab with chemotherapy against current immunotherapy-based standards of care," said Deirdre J. Cohen, MD, MS, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai and lead investigator for the study.
Detailed results from the HARMONi-GI1 study will be presented at the European Society for Medical Oncology 2026 Congress on Sunday, October 25.
Akeso has licensed the exclusive rights to develop and commercialize ivonescimab in the United States, Canada, South America, Europe, the Middle East, Africa, and Japan to Summit Therapeutics under an agreement with a total potential value of up to $5 billion.
More than 18 Phase III studies of ivonescimab are currently underway globally across multiple tumor types.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
c1bd43448b· 2026-10-21 20:51 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前